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Background: Atrial fibrillation is a frequent co-morbidity in patients with chronic heart failure (HF) which contributes to worse outcomes. The 
CHAMPION trial demonstrated a significant reduction in the rate of HF hospitalizations in patients with pulmonary artery pressure monitor guided 
treatment. We postulated that patients with a history of atrial fibrillation (hAF) would exhibit worse baseline co-morbidities when compared to the 
normal sinus group, and hAF patients with physician access to remote pulmonary artery pressure data would have a significant reduction in the rate 
of HF hospitalizations.
Methods: We retrospectively analyzed the CHAMPION results to determine the effectiveness of pulmonary artery pressure guided therapy in a 
subgroup of patients with hAF. All patients received standard HF medical therapy. The primary endpoint was adjudicated HF hospitalizations analyzed 
with the negative binomial regression.
Results: Of the 550 NYHA class III CHAMPION patients, 255 (46.4%) had hAF at baseline; randomized to treatment (120) or control (135). The 
patients with hAF exhibited significant baseline differences compared to those in sinus rhythm: they were older (65 vs.59), more often male (80% 
vs.66%), white (81% vs.66%), more frequently had CRT or CRT-D devices (44% vs. 27%), had worse renal function by GFR (56 vs. 65 ml/min), and 
higher mean PA pressures (30.2 vs. 28.5 mmHg). Additionally, patients with a history of AF had a 57% higher HF hospitalization rate at 6 months 
compared to non AF ( 0.47 vs 0.30 events/patient p < 0.0001. Treatment patients with hAF had a 37% lower 6 month and a 41% lower 15 month 
( total blinded follow-up) rate of HF hospitalizations compared to control patients (0.36 vs. 0.57); p = 0.0004; and 0.54 vs. 0.91 (p< 0.0001) 
respectively.
Conclusions: In patients with NYHA class III heart failure implanted with a wireless hemodynamic monitor; those with hAF had worse baseline co-
morbidities and more frequent HF hospitalizations than those in sinus rhythm. hAF patients randomized to access to pulmonary artery pressures had 
fewer heart failure hospitalizations than those assigned to standard care.
